Article Per Year (5 Year)
p-Index From 2021 - 2026
1.325
P-Index
This Author published in this journals
All Journal Jurnal MIPA PHARMACON Narra J
Trina E. Tallei, Trina E.
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Mathematics Medicine & Pharmacology Physics Public Health

Published : 15 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search
Journal : Narra J

 1 
Clinical and oral microbiome pattern of halitosis patients with periodontitis and gingivitis Ningsih, Diana S.; Idroes, Rinaldi; Bachtiar, Boy M.; Khairan, Khairan; Tallei, Trina E.; Kemala, Pati; Maulydia, Nur B.; Idroes, Ghazi M.; Helwani, Zuchra
Narra J Vol. 3 No. 2 (2023): August 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i2.163

Abstract

Halitosis is caused by a bacterial proteolytic process that induces the production of volatile sulfur compounds, odor-causing gases. The aim of this study was to determine the clinical oral hygiene state and oral microbiome pattern of halitosis patients with periodontitis and gingivitis. The oral hygiene state of halitosis patients with periodontitis and gingivitis was assessed using the oral hygiene index simplified (OHI-S), decay missing filled teeth (DMFT), and tongue biofilm. The dorsum of the tongue and subgingival swabs were cultured for bacteria, and bacterial morphology was evaluated using Gram staining. Evaluation of the bacterial genus using the Bergey's systematic bacteriology diagram as a guide. A total of ten patients with periodontitis and gingivitis were included. Our data indicated that the scores of OHI-S and DMFT were different significantly between halitosis patients with periodontitis and gingivitis (both had p<0.001) while tongue biofilm score was not different between groups. On the dorsum of the tongue, periodontitis patients had a significant higher oral microbiome population (85.65x106 CFU/mL) compared to those with gingivitis (0.047x106 CFU/mL) with p=0.002. In contrast, the number of microbiomes in the subgingival had no significant different between periodontitis and gingivitis. On the dorsum of the tongue, six bacterial genera were isolated from periodontitis cases and seven genera were detected from gingivitis patients. On subgingival, 10 and 15 genera were identified from periodontitis and gingivitis, respectively. Fusobacterium, Propionibacterium, Eubacterium and Lactobacillus were the most prevalent among periodontitis cases while Porphyromonas was the most prevalent in gingivitis patients. In conclusion, although OHI-S and DMFT are different between periodontitis and gingivitis, overlapping of bacterial genera was detected between periodontitis and gingivitis cases.
Uncovering anti-inflammatory potential of Lantana camara Linn: Network pharmacology and in vitro studies Khairan, Khairan; Maulydia, Nur B.; Faddillah, Vira; Tallei, Trina E.; Fauzi, Fazlin M.; Idroes, Rinaldi
Narra J Vol. 4 No. 2 (2024): August 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i2.894

Abstract

Lantana camara Linn contains a diverse array of metabolites that exhibit therapeutic potential. The aim of this study was to evaluate the potential of L. camara leaves, which were collected at the Ie-Seu'um geothermal area in Aceh, Indonesia, as an anti-inflammatory through network pharmacology and in vitro analysis. The ethanolic extract derived from L. camara underwent identification utilizing gas chromatography-mass spectrometry (GC-MS) to verify chemical constituents for drug-likeness properties. The evaluation of anti-inflammatory activity included network pharmacology and a series of in vitro investigations using two methods: protein inhibition and albumin denaturation assays. The findings revealed that the extract contained a domination of terpenoids and fatty acids class, which met the evaluation criteria of drug-likeness. Network pharmacology analysis identified the top five key proteins (peroxisome proliferator-activated receptor gamma, prostaglandin G/H synthase 2, epidermal growth factor receptor, hypoxia-inducible factor 1-alpha, and tyrosine protein kinase-Janus kinase 2) involved in inflammation-related protein-protein interactions. Gene ontology enrichment highlighted the predominance of inflammatory responses in biological processes (BP), cytoplasm in cellular components (CC), and oxidoreductase activity in molecular functions (MF). In vitro analysis showed that the extract inhibited protein activity and protein denaturation with inhibitory concentration (IC50) values of 202.27 and 223.85 ppm, respectively. Additionally, the extract had antioxidant activity with DPPH- and ABTS-scavenging IC50 values of 140 ppm and 163 ppm, respectively. Toxicological assessment by brine shrimp lethality assay (BSLA), yielding a lethal concentration (LC50) value of 574 ppm (essentially non-toxic) and its prediction via ProTox 3.0 that indicated non-active in hepatotoxicity, carcinogenicity, immunotoxicity, mutagenicity, and cytotoxicity. These results suggested that L. camara holds noteworthy effectiveness as a potential candidate for complementary medicine in the realm of inflammatory agents, warranting further investigation in clinical settings.
A network pharmacology approach to elucidate the anti-inflammatory and antioxidant effects of bitter leaf (Vernonia amygdalina Del.) Sailah, Illah; Tallei, Trina E.; Safitri, Linda; Tamala, Yulianida; Halimatushadyah, Ernie; Ekatanti, Dewi; Maulydia, Nur B.; Celik, Ismail
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.1016

Abstract

The therapeutic potential of bitter leaf (Vernonia amygdalina Del.) has been established both empirically and in various scientific investigations. However, the molecular pathways related to its possible anti-inflammatory and antioxidant properties remain unclear. Therefore, the aim of this study was to elucidate the molecular interactions between bitter leaf's bioactive compounds and cellular targets involved in these activities. The compounds in bitter leaf were identified using gas chromatography-mass spectrometry (GC-MS) analysis, and subsequently, a network pharmacology approach was employed together with molecular docking and dynamics simulations. Acetonitrile (4.5%) and dimethylamine (4.972%) were the most prevalent compounds among the 38 identified by the GC-MS analysis of bitter leaf extract. The proto-oncogene tyrosine-protein kinase (SRC) demonstrated significant connectivity within the antioxidant network, highlighting its pivotal role in facilitating inter-protein communication. It also exhibited strategic positioning in anti-inflammatory mechanisms based on closeness centrality (0.385). The enrichment analysis suggested multifaceted mechanisms of bitter leaf compounds, including transcriptional regulation and diverse cellular targeting, indicating broad antioxidant and anti-inflammatory effects. Eicosapentaenoyl ethanolamide (EPEA) displayed strong interactions with multiple proteins, including SRC (-7.17 kcal/mol) and CYP3A4 (-6.88 kcal/mol). Moreover, EPEA demonstrated to form a stable interaction with SRC during a 100 ns simulation. In conclusion, the computational simulations revealed that the hypothetical antioxidant and anti-inflammatory actions of bitter leaf compounds were achieved by specifically targeting SRC. However, confirmation using either in vitro or in vivo techniques is necessary.
Mechanistic insights into the anticancer, anti-inflammatory, and antioxidant effects of yellowfin tuna collagen peptides using network pharmacology Kairupan, Tara S.; Kapantow, Nova H.; Tallei, Trina E.; Niode, Nurdjannah J.; Sanggelorang, Yulianty; Rotty, Linda WA.; Wungouw, Herlina IS.; Kawengian, Shirley ES.; Fatimawali, Fatimawali; Maulydia, Nur B.
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1885

Abstract

Marine-derived collagen peptides have been acknowledged for their therapeutic potential, especially in cancer therapy and inflammation management. The aim of this study was to investigate the molecular mechanisms that contribute to the anticancer, anti-inflammatory and antioxidant properties of yellowfin tuna collagen peptides (YFTCP) utilizing a network pharmacology approach. The YFTCP was extracted from the bones of yellowfin tuna (Thunnus albacares) and subsequently hydrolyzed with trypsin. Seventeen peptides were discovered using liquid chromatography in conjunction with high-resolution mass spectrometry (LC-HRMS). A network pharmacology method was utilized to investigate the interactions between the discovered peptides and their biological targets. Additionally, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to identify pertinent biological pathways involved in the anticancer, antioxidant, and anti-inflammatory effects of these peptides. GO analysis revealed key associations between YFTCP and critical cancer- and inflammation-related genes encoding proteins such as CCND1, SRC, AKT1, IL-1β, TNF, and PPARG, which exhibited significant interactions. These proteins are essential for the regulation of the cell cycle, the development of tumors, and the response to inflammatory stimuli. The KEGG analysis also revealed that YFTCP was involved in a number of critical pathways, such as endocrine resistance, cancer pathways, Kaposi sarcoma-associated herpesvirus infection, proteoglycans in cancer, and human cytomegalovirus infection. These findings highlight the potential use of YFTCP as a multifaceted therapeutic agent, indicating their role in regulating important biological pathways associated with cancer development and inflammation. This study provides new valuable insights into the pharmacological properties of YFTCP, paving the way for future studies and drug development focused on these bioactive peptides.
Dual anti-inflammatory and antimicrobial effects of stingless bee propolis on second-degree burns Manginstar, Christian O.; Tallei, Trina E.; Salaki, Christina L.; Niode, Nurdjannah J.; Jaya, Hendra K.
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.2359

Abstract

Propolis, a natural resinous product from stingless bees, is widely recognized for its anti-inflammatory and antimicrobial properties. However, its combined effects in addressing both inflammation and infection in second-degree burns have remained insufficiently explored. The study aimed to investigate the dual role of propolis in modulating inflammation and preventing bacterial infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in a second-degree burn model. Propolis was collected from stingless bees in Gowa, South Sulawesi, Indonesia, and extracted using methanol. Second-degree burns were induced in male Rattus norvegicus, which were then divided into three groups: one treated with propolis, another silver sulfadiazine (positive control), and third with NaCl (negative control). After seven days of treatment, the expression of tumor necrosis factor-alpha (TNF-α) and vascular endothelial growth factor (VEGF) proteins in wound samples was analyzed using immunohistochemistry. The antimicrobial activity of the propolis extract was assessed using the disc diffusion assay, followed by minimum inhibitory concentration (MIC) testing. Network pharmacology analysis was also conducted to assess the anti-inflammatory activity of propolis. Results showed that propolis significantly reduced TNF-α expression and increased VEGF expression, which might enhance VEGF-mediated angiogenesis, leading to improved wound healing compared to controls. The antimicrobial tests demonstrated strong activity against MRSA and P. aeruginosa, with inhibition zones correlating with higher extract concentrations. The MIC value of the propolis extract was 198.66 µg/µL against MRSA and 212.06 µg/µL against P. aeruginosa. Network pharmacology analysis revealed key proteins, including Jun proto-oncogene (JUN), estrogen receptor 1 (ESR1), signal transducer and activator of transcription 3 (STAT3), and proto-oncogene tyrosine-protein kinase Src (SRC), involved in the regulation of TNF-α and VEGF, further supporting the synergistic effects of propolis. This study demonstrates that stingless bee propolis effectively promotes tissue regeneration and prevents infection in second-degree burns, highlighting its potential as an alternative to conventional treatments for wound care.
Probiotic Lactobacillus sp. as a strategy for modulation of non-comorbid obesity: A systematic meta-analysis and GRADE assessment of randomized controlled trials Lele, Juan AJMN.; Sihaloho, Karlos B.; Vighneswara, Dewa; Rampengan , Derren DCH.; Rizqiansyah, Chrisandi Y.; Permatasari, Happy K.; Mayulu, Nelly; Tallei, Trina E.; Taslim, Nurpudji A.; Kim, Bonglee; Kezia, Immanuelle; Nurkolis, Fahrul; Syahputra, Rony A.
Narra J Vol. 5 No. 2 (2025): August 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i2.1562

Abstract

Given the high prevalence of obesity worldwide, effective therapeutic strategies are crucial to prevent and manage obesity-related health conditions. Existing studies indicate that Lactobacillus sp. showed beneficial effects on body weight and adiposity by modifying the gut microbiota; however, no meta-analysis has been conducted assessing the efficacy of Lactobacillus sp-based probiotics on anthropometric parameters, leptin and adiponectin levels, and gut microbiota composition. The aim of this study was to evaluate the efficacy and safety of probiotic supplementation with Lactobacillus sp. in obese individuals without comorbidities. A systematic search was conducted on November 28, 2024, using five databases: PubMed, Wiley, ScienceDirect, Epistemonikos, and Cochrane. Primary outcomes included changes in body mass index (BMI), body weight, waist and hip circumferences, visceral and subcutaneous fat areas, and total body fat content. Secondary outcomes included alterations in leptin and adiponectin levels, gut microbiota composition, and the incidence of adverse events. A total of 1,058 individuals were included across 12 clinical trials. Significant reductions were observed in BMI (mean difference (MD): -0.40 kg/m²; 95%CI: -0.48–(-0.32), p<0.00001), body weight (MD: -1.16 kg; 95%CI: -1.79–(-0.53), p=0.0003), waist circumference (MD: -1.41 cm; 95%CI: -1.75–(-1.08), p<0.00001), and hip circumference (MD: -0.85 cm; 95%CI: -1.09–(-0.61), p<0.00001) compared to controls. Additionally, compared to control group, significant reductions were observed in visceral and subcutaneous fat mass (MD: -7.35; 95%CI: -9.95–(-4.75); p<0.00001) and overall body fat (MD: -1.11; 95%CI: -1.31–(-0.91); p<0.00001). Leptin levels significantly decreased (MD: -2.11 μg/mL; 95%CI: -3.59–(-0.64), p=0.005) compared to before Lactobacillus sp. supplementation, while adiponectin levels increased (MD: 0.71 μg/mL; 95%CI: 0.22–1.20, p=0.004) following Lactobacillus sp. supplementation compared to placebo group. No significant adverse events were reported in either the intervention or control groups. In conclusion, Lactobacillus sp. probiotic supplementation may serve as an adjuvant therapy to enhance obesity management in non-comorbid obese individuals.
Co-Authors Astuti, Feni P. Bawole, Kevin V. Boy M. Bachtiar Celik, Ismail Christina Salaki Claudius F. Kairupan, Claudius F. Datu, Olvie S. Ekatanti, Dewi Faddillah, Vira Fatimawali . Fauzi, Fazlin M. Gani, Maria A. Gracia Alice Victoria Pollo Halimatushadyah, Ernie Idroes, Ghazi M. Illah Sailah Jaya, Hendra K. Kairupan, Tara S. Kawengian, Shirley ES. Kemala, Pati Kezia, Immanuelle Khairan Khairan Kim, Bonglee Lele, Juan AJMN. Linelejan, Yosua Th. Manginstar, Christian O. Maulydia, Nur B. Mohtar, Khumairah Nelly Mayulu Ningsih, Diana S. Nova Hellen Kapantow Nurdjannah J. Niode Nurkolis, Fahrul Nurpudji A. Taslim Permatasari, Happy K. Rampengan , Derren DCH. Rinaldi Idroes Rizqiansyah, Chrisandi Y. Roni Koneri Rooije R.H. Rumende Rotinsulu, Sarah Rotty, Linda WA. Rumondor, Erladys M. Safitri, Linda Sihaloho, Karlos B. Sumeisey, Gabriella Sumual, Acika Syahputra, Rony A. Tamala, Yulianida Umboh, Stela D. Umboh, Stella D. Vighneswara, Dewa Wungouw, Herlina IS. Yulianty Sanggelorang Zuchra Helwani, Zuchra